GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Solid Biosciences Inc (NAS:SLDB) » Definitions » Equity-to-Asset

Solid Biosciences (Solid Biosciences) Equity-to-Asset : 0.85 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Solid Biosciences Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Solid Biosciences's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $210.72 Mil. Solid Biosciences's Total Assets for the quarter that ended in Mar. 2024 was $248.69 Mil.

The historical rank and industry rank for Solid Biosciences's Equity-to-Asset or its related term are showing as below:

SLDB' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.08   Med: 0.77   Max: 0.9
Current: 0.77

During the past 9 years, the highest Equity to Asset Ratio of Solid Biosciences was 0.90. The lowest was -2.08. And the median was 0.77.

SLDB's Equity-to-Asset is ranked better than
63.07% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs SLDB: 0.77

Solid Biosciences Equity-to-Asset Historical Data

The historical data trend for Solid Biosciences's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Solid Biosciences Equity-to-Asset Chart

Solid Biosciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only 0.77 0.77 0.90 0.81 0.77

Solid Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.80 0.80 0.78 0.77 0.85

Competitive Comparison of Solid Biosciences's Equity-to-Asset

For the Biotechnology subindustry, Solid Biosciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Solid Biosciences's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Solid Biosciences's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Solid Biosciences's Equity-to-Asset falls into.



Solid Biosciences Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Solid Biosciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=126.481/164.939
=

Solid Biosciences's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=210.724/248.689
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Solid Biosciences  (NAS:SLDB) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Solid Biosciences Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Solid Biosciences's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Solid Biosciences (Solid Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
500 Rutherford Avenue, Third Floor, Charlestown, MA, USA, 02129
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
Executives
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Perceptive Life Sciences Master Fund Ltd director, 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Kevin Tan officer: CFO & Treasurer 20 HICKORY ROAD, WELLESLEY MA 02482
Ilan Ganot director, officer: Chief Executive Officer C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
David T Howton officer: See Remarks VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
Jennifer Marlowe officer: CSO, FA & Cardiac 500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN MA 02129
Paul Herzich officer: Chief Technology Officer 500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN MA 02129
Jessie Hanrahan officer: Chief Regulatory Officer 500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN MA 02129
Gabriel Brooks officer: Chief Medical Officer C/O SOLID BIOSCIENCES INC., 500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN MA 02129
Carl Ashley Morris officer: Chief Scientific Officer C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Georgia Keresty director C/O ASPEN TECHNOLOGY, INC., 20 CROSBY DRIVE, BEDFORD MA 01730
Clare Kahn director 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Ian F Smith director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Bcls Sb Investco, Lp 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Bcls Ii Investo (gp), Llc 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116

Solid Biosciences (Solid Biosciences) Headlines

From GuruFocus

Solid Biosciences Announces a 1-for-15 Reverse Stock Split

By Value_Insider Value_Insider 10-27-2022